QualityDipStocks / Finance · Consumer finance
Core Scientific CORZ
Outside our quality screen, so we don’t track its dips. It’s 57% below its 52-week high.
Outside our quality screen, 20% under its Market Value. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Down 59% from its 52-week high while revenue grew 26%
- Share count down 7% in 3 years
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $15.73price −20%
- Off 52-wk high
- −57%
- Risk vs market
- Highbeta 3.06
2 bullish · 5 bearish See why
Repriced or dip?
Dip: business intact
The price is 57% below its 52-week high (Jun 18), but the business held up: revenue +24.1%, revenue growth rate +40.0 pts, operating margin +16.0 pts.
Some numbers held up (revenue +24.1%, revenue growth rate +40.0 pts, operating margin +16.0 pts), others slipped (net cash (cash minus debt) −36.9% of market cap since the high). The price is 57% below its 52-week high.
The price is 57% below its 52-week high, and the business changed too: net cash (cash minus debt) −36.9% of market cap since the high.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 7 numbers, high vs now
- Revenue, last 12 months$355M → $440M (+24.1%)held up
- Revenue growth rate−13.7% → +26.4% a year (+40.0 pts)held up
- Operating margin−143.5% → −127.4% (+16.0 pts)held up
- Shares outstanding−0.9% (fewer shares, each owns more)held up
- Net cash (cash minus debt)−36.9% of market cap since the highchanged
- Stock vs its sector (Finance)stock −57%, sector median +4% since Jun 18changed
- Price fall vs business numbersprice −57%, revenue/EPS/FCF median +24% (shown, not scored)
Business numbers as reported at the high (12 months to Mar 31, 2026) vs the latest filing (12 months to Jun 30, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for CORZ: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much CORZ moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings much more than the market, and its own price swings are 5.7× the S&P 500’s.
- Beta vs S&P 500
- 3.06
- Volatility
- 73% vs 13% SPY
- Correlation SPY
- 0.53
- Correlation QQQ
- 0.60
Valuation details
MV $15.73
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 2 of 5
GrowthSales grew 26% to $440M over the last 12 months vs the 12 months before (SEC filings).
ValuationTrades 20.5% below its Market Value of $15.73, the average price paid since the Aug 27 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$958M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityOperating margin narrowed to −77.0% in FY2025 from 1.8% in FY2023 (SEC filings).
ProfitabilityGross margin narrowed to 11.9% in FY2025 from 24.6% in FY2023 (SEC filings).
ProfitabilityLost $1.6B over the last 12 months (net income, SEC filings).
GrowthSales shrank 21% a year from FY2022 to FY2025.
All fundamentals
FCF yield -23.9% · Sales +26%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −23.9%
- EV / EBITDA
- n/anegative EBITDA
- Price / sales
- 9.08×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $4.0Blisted
- Enterprise value
- $6.5B
Growth
- Revenue, 12 months
- $440M
- Sales growth, 12 months
- +26.4%vs the 12 months before
- Sales growth, 3 yrs
- −20.7%/yrfrom FY2022
- Diluted EPS, 12 months
- −$5.04
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$1.6B
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 28.3%
- Operating margin
- −127.4%
- Net margin
- n/an/m
- FCF margin
- n/an/m: revenue near zero
- Return on equity
- n/anegative shareholder equity
- Return on invested capital
- n/an/m: very small invested capital
Balance sheet
- Cash & short-term inv.
- $1.8B
- Total debt
- $4.3B
- Net cash
- −$2.5B
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$958M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +2.3%diluted shares vs a year ago
- Stock-based comp
- $94M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Core Scientific’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.5B · Sales +109%
- Free cash flow, 12 months$0.5B
- Free-cash-flow yield-23.9%
- Sales growth (latest quarter vs year-ago quarter)+109%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $12.51
- 52-wk lowlowest close, 1 year$12.51at the price
- PriceMon Nov 2 close$12.51you are here
- Market Valueavg paid since Aug 27$15.73+25.7%
- 52-wk highhighest close, 1 year$29.16+133.1%
Momentum & 52-week range
RSI 36 · 5 days −7.4%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 5
- DateThu Nov 5, before the open
- Consensus EPS$0
- Year-ago EPS($0.46)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
CORZ is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Core Scientific in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Consumer finance
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.